Işıl AYDEMİRSeda VATANSEVERKemal ÖZBİLGİN2024-07-242024-07-2420191303-829Xhttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/22457Background: HAMLET (human α-lactalbumin made lethalto tumor cells) and sulindac are active ingredients whichare used in the treatment of cancers. Under both in vivo andin vitro conditions, HAMLET binds to the surface of tumorcells and enters the cells. Sulindac is one of nonsteroidalanti-inflammatory drugs. It inhibits the growth of tumorcells by inducing the apoptosis. In our study, we aimed toinvestigate effects of α-lactalbumin and sulindac on COLO320 primary and COLO-741 metastatic human colon carcinoma cell lines via mitochondrial apoptotic pathway byindirect immunocytochemistry and TUNEL assays.Materials and methods: The effects of α-lactalbuminand sulindac were assessed by using MTT assay at 24, 48and 72 h and apoptosis markers caspase-3, caspase-9 andcytochrome-c were detected using immunocytochemistryand TUNEL methods.Results: It was appeared that α-lactalbumin and sulindacmay triggger mechanisms of apoptosis in both primaryand metastatic colon carcinoma cell lines and the primarycolon carcinoma cell line was affected more than the metastatic cells.Conclusion: It is proposed that α-lactalbumin and sulindac can be used in cancer treatments and future in vivoexperiments.engAraştırma Makalesi10.1515/tjb-2017-0263